BSEKabra Drugs LtdLowNeutral
Announced Tue, 30 Sept · 09:42 IST

Outcome and Proceedings of Annual General Meeting

Board & Shareholder Meetings View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Kabra Drugs Limited held its 36th Annual General Meeting on 30th September 2025 at Ginger Hotel, Indore, from 9:00 AM to 9:30 AM. The meeting was chaired by Managing Director Mr. Nanjappan Aravind, with all required quorum, statutory auditors, secretarial auditors, and a scrutinizer (Mr. CS Jay Jain) present. Four items of business were transacted: adoption of audited financial statements for FY ended 31st March 2025 (ordinary resolution), re-appointment of Mr. Kuniamuthur Nanjappan Anand as director retiring by rotation (ordinary resolution), approval of his remuneration (special resolution), and appointment of Mr. Tanuj Jain Susilkumar as Secretarial Auditor for a 5-year term (special resolution). Remote e-voting was held from 27–29 September 2025, and combined voting results will be announced within 48 hours and filed with the stock exchange separately.

Likely market impact

This is a routine AGM with no major corporate surprises. Shareholders should watch for the voting results filing within 48 hours to confirm approval of the special resolutions, particularly the executive remuneration and the new 5-year secretarial auditor appointment.